Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | RESMAIN: resmonistat for CTCL maintenance

Pablo Ortiz Romero • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Resminostat
RESMAIN

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, discusses the need for improved maintenance therapies in cutaneous T-cell lymphoma (CTCL), highlighting the potential benefits of resminostat which is being explored in the RESMAIN trial (NCT02953301). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Pablo Ortiz Romero

0:58
Approval of brentuximab vedotin for CD30+ mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
1:13
Novel therapies on the horizon for CTCL
Pablo Ortiz Romero • 14 Oct 2021
1:23
Pegylated liposomal doxorubicin as maintenance in mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
0:38
Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab
Pablo Ortiz Romero • 14 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals